Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Montserrat Vera-LlonchGerry Oster

Abstract

To compare expected outcomes and costs of care in patients with chronic schizophrenia or schizoaffective disorders who are treated with risperidone versus olanzapine. A Markov model was developed to examine outcomes and costs of care in patients with chronic schizophrenia or schizoaffective disorders receiving risperidone or olanzapine. The time frame of interest was 1 year. The model focused particular attention on the likelihood of therapy switching and discontinuation as a result of treatment-emergent side effects, as the efficacy of these two agents is similar. Measures of interest included the incidence of relapse and selected side effects including extrapyramidal symptoms (EPS), prolactin-related disorders and diabetes, expected change in body weight, and the percentage of patients remaining on initial therapy at the end of 1 year. Costs of antipsychotic therapy and psychiatric and nonpsychiatric services also were examined. At 1 year, the rate of EPS was estimated to be slightly higher for risperidone, as was the incidence of symptomatic prolactin-related disorders. The expected incidence of diabetes mellitus, while low, was slightly higher for olanzapine. Approximately 25% and 4% of olanzapine and risperidone patients, ...Continue Reading

References

Feb 1, 1992·Journal of the American College of Nutrition·A B SpielmanG L Blackburn
Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Jul 1, 1995·The American Journal of Psychiatry·R A DicksonA L Edwards
Oct 1, 1993·Medical Decision Making : an International Journal of the Society for Medical Decision Making·F A Sonnenberg, J R Beck
Oct 1, 1993·Annals of Internal Medicine·F X Pi-Sunyer
Jun 1, 1996·The American Journal of Psychiatry·J R BustilloA Breier
Jan 1, 1996·Comprehensive Psychiatry·S MukherjeeP L Scapicchio
May 1, 1996·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·H Pijl, A E Meinders
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C M BeasleyS Hamilton
Dec 1, 1995·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M HummerW W Fleischhacker
May 1, 1997·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·C M BeasleyJ N Beuzen
Mar 31, 1998·The British Journal of Psychiatry : the Journal of Mental Science·S Brown
Oct 30, 1998·Journal of Psychiatric Research·J R DeQuardo, R Tandon
Nov 7, 1998·The Australian and New Zealand Journal of Psychiatry·D Briffa, T Meehan
Jan 28, 1999·The Journal of Clinical Psychiatry·M K FertigC W English
Feb 6, 1999·Journal of Clinical Psychopharmacology·D L KleinbergM Brecher
Jun 9, 1999·The American Journal of Psychiatry·S K OberA Rusterholtz
Sep 24, 1999·Current Medical Research and Opinion·B Green
Dec 10, 1999·The Journal of Clinical Psychiatry·D N OsserR L Dufresne
Jan 19, 2000·Medical Decision Making : an International Journal of the Society for Medical Decision Making·B A CraigP P Sendi
Jun 1, 2000·The American Journal of Psychiatry·D C HendersonD C Goff
Aug 10, 2000·Medical Decision Making : an International Journal of the Society for Medical Decision Making·E F HalpernG S Gazelle
Nov 22, 2000·Schizophrenia Bulletin·L DixonA Lehman
Feb 24, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·T Wetterling
Mar 16, 2001·Journal of Psychiatric and Mental Health Nursing·R Gray, K Gournay
Jun 1, 2001·The American Journal of Psychiatry·D UmbrichtR Bridler
Sep 18, 2001·JAMA : the Journal of the American Medical Association·A H MokdadJ P Koplan
Nov 3, 2001·JAMA : the Journal of the American Medical Association·B Luna, M N Feinglos
Jan 14, 2003·The Journal of Clinical Psychiatry·J Jaime CaroKimberly Robinson
Feb 26, 2004·Obesity Research·UNKNOWN American Diabetes AssociationUNKNOWN North American Association for the Study of Obesity

❮ Previous
Next ❯

Citations

Jul 4, 2012·Annals of General Psychiatry·Thomas R EinarsonMichiel E H Hemels
Jul 26, 2012·Health Economics Review·Antonio J García-RuizMiguel A Casado
Jul 16, 2008·PharmacoEconomics·Bart M S HeegBen A van Hout
Feb 26, 2014·Expert Review of Pharmacoeconomics & Outcomes Research·Birgitta von SchéeleAnita Patel
Jul 5, 2011·Expert Review of Neurotherapeutics·Maurizio PompiliPaolo Girardi
Oct 29, 2008·Current Medical Research and Opinion·Natalie C EdwardsRiad Dirani
Jun 28, 2014·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Taehwan Park, Karen M Kuntz
Jun 15, 2019·Expert Review of Pharmacoeconomics & Outcomes Research·Ben F M WijnenJoran Lokkerbol
Aug 22, 2018·Journal of Market Access & Health Policy·Junwen ZhouMondher Toumi
Apr 9, 2009·Cost Effectiveness and Resource Allocation : C/E·Nicolas M FuriakSteven D Culler

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.